Published on
Feb 20, 2025
Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with ...
Ingelheim, Germany, 20 February 2025 – Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)1 and OXB,1 today announce the start of LENTICLAIRTM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, gene therapy …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
